These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 8299565)

  • 1. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.
    Hickey G; Jacks T; Judith F; Taylor J; Schoen WR; Krupa D; Cunningham P; Clark J; Smith RG
    Endocrinology; 1994 Feb; 134(2):695-701. PubMed ID: 8299565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.
    Jacks T; Hickey G; Judith F; Taylor J; Chen H; Krupa D; Feeney W; Schoen W; Ok D; Fisher M
    J Endocrinol; 1994 Nov; 143(2):399-406. PubMed ID: 7830002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine.
    Chang CH; Rickes EL; Marsilio F; McGuire L; Cosgrove S; Taylor J; Chen H; Feighner S; Clark JN; De Vita R
    Endocrinology; 1995 Mar; 136(3):1065-71. PubMed ID: 7867560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
    Chang CH; Rickes EL; McGuire L; Frazier E; Chen H; Barakat K; Nargund R; Patchett A; Smith RG; Hickey GJ
    Endocrinology; 1996 Nov; 137(11):4851-6. PubMed ID: 8895356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
    Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
    Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
    Gertz BJ; Barrett JS; Eisenhandler R; Krupa DA; Wittreich JM; Seibold JR; Schneider SH
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1393-7. PubMed ID: 8077339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebroventricular and intravenous administration of growth hormone secretagogue L-692,585, somatostatin, neuropeptide Y and galanin in pig: dose-dependent effects on growth hormone secretion.
    Cho SJ; Lee JS; Mathias ED; Chang C; Hickey GJ; Lkhagvadorj S; Anderson LL
    Comp Biochem Physiol C Toxicol Pharmacol; 2010 May; 151(4):412-9. PubMed ID: 20074661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of adrenocorticotropin in the cortisol and aldosterone responses to angiotensin II in conscious dogs.
    Brooks VL; Daneshvar L; Reid IA
    Endocrinology; 1988 Jan; 122(1):97-104. PubMed ID: 2826116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585.
    Hickey GJ; Drisko J; Faidley T; Chang C; Anderson LL; Nicolich S; McGuire L; Rickes E; Krupa D; Feeney W; Friscino B; Cunningham P; Frazier E; Chen H; Laroque P; Smith RG
    J Endocrinol; 1996 Feb; 148(2):371-80. PubMed ID: 8699151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study.
    Chapman IM; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2874-80. PubMed ID: 8768844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary and extrapituitary action sites of the novel nonpeptidyl growth hormone (GH) secretagogue L-692,429 in the chicken.
    Geris KL; Hickey GJ; Berghman LR; Visser TJ; Kühn ER; Darras VM
    Gen Comp Endocrinol; 1998 Aug; 111(2):186-96. PubMed ID: 9679090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of pituitary function after transsphenoidal hypophysectomy in beagle dogs.
    Meij BP; Mol JA; van den Ingh TS; Bevers MM; Hazewinkel HA; Rijnberk A
    Domest Anim Endocrinol; 1997 Mar; 14(2):81-97. PubMed ID: 9063651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH)-releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels.
    Kineman RD; Kamegai J; Frohman LA
    Endocrinology; 1999 Aug; 140(8):3581-6. PubMed ID: 10433214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
    Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response effects of exogenous pulsatile human corticotropin-releasing hormone on adrenocorticotropin, cortisol, and gonadotropin concentrations in agonadal women.
    Thomas MA; Rebar RW; LaBarbera AR; Pennington EJ; Liu JH
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1249-54. PubMed ID: 1851183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion.
    Gertz BJ; Sciberras DG; Yogendran L; Christie K; Bador K; Krupa D; Wittreich JM; James I
    J Clin Endocrinol Metab; 1994 Sep; 79(3):745-9. PubMed ID: 8077355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraventricular nucleus mediates prolactin secretory responses to restraint stress, ether stress, and 5-hydroxy-L-tryptophan injection in the rat.
    Minamitani N; Minamitani T; Lechan RM; Bollinger-Gruber J; Reichlin S
    Endocrinology; 1987 Mar; 120(3):860-7. PubMed ID: 3542515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.